The First Condor Life and OBiO Technology have reached a strategic cooperation. In this collaboration, The First Condor Life and OBiO Technology will share resources, complement each other's advantages, jointly address market changes and competitive pressures, and achieve win-win cooperation and sustainable development.
With the vigorous development of biomedicine, lentiviral vectors, due to their characteristics of safety, stable integration and expression, and the ability to carry large gene segments, have been widely used as a core tool for gene delivery in both basic research and clinical treatment. Scientists continue to conduct in-depth research on lentiviral vectors, and their many iterations have laid the foundation for industry development. CAR-NK therapy is expected to become another blockbuster product after CAR-T therapy. The gene delivery of NK cells is an extremely important part of the CAR-NK production process and is currently a significant industry challenge. Solving the problem of efficiently transducing NK cells with lentiviruses can provide strong support for the development of CAR-NK therapy.
First Condor Life's co-founder and CTO, Maria Ma, expressed deep gratitude for the trust and support from OBiO Tech. She stated, “We are delighted to collaborate with OBiO Tech to explore possibilities in the field of life sciences. First Condor Life has been committed to developing cell therapies for solid tumors, including CAR-T and CAR-NK. In this collaboration we are focusing on lentiviral system specifically designed for NK cells. The modified and optimized lentiviral system achieved a breakthrough in the efficiency of NK cell infection, which will have profound implications for NK cell based research and drug development. As a leading CDMO company, OBiO Tech possesses excellent technical capabilities and market promotion abilities. Through Leveraging the strengths of both parties, we believes that this collaboration will not only bring mutual benefits but will also make a positive contribution to the entire industry and society”
CEO of OBiO Biotech, Guodong Jia, expressed his pleasure in establishing a strategic cooperation with First Condor Life, emphasizing that OBiO Tech has consistently focused on the fields of gene and cell therapy, with the mission of "enable gene therapy for better lives”. The company specializes in the research and development of viral vectors and large-scale manufacturing. as its two core technology clusters and continuously commits to addressing challenges to meet the unmet needs of customers and patients. Since its establishment, the company has consistently pursued technological innovation, balancing between independent research and development and external collaboration in order to make innovative breakthroughs to empower industry development. Looking ahead, OBiO Biotech expects that the lentiviral system for NK cells developed in this collaboration can be utilized by more researchers or pharmaceutical companies, maximizing its value.
He expressed the hope for sincere cooperation between the two parties, anticipating that more collaboration in the future.
About OBiO Technology
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, SSE:688238.SH) was established in 2013. It is a biotechnology company focusing in the field of gene and cell therapy, providing CRO and CDMO services such as viral vector development and gene function study for basic research as well as CMC development and GMP manufacture of plasmids, viral vectors, oncolytic viruses, CAR-T cell therapy products, With "enable gene therapy for better lives" as our mission, we are committed to providing high-quality service to global customers, advancing product from bench to clinic, and bringing benefit to patients around the world. For more information about OBiO, visit www.obio-tech.com.
About First Condor Life
First Condor Life Science Co., Ltd. was established in March 2020 in Shenzhen, with its research and production base located in the Songshan Lake High-tech Zone in Dongguan. It is a national high-tech enterprise dedicated to the research and industrialization of solid tumor cell immunotherapy. The company, guided by independent research and development of CAR-T products, simultaneously explores international cutting-edge technologies such as CAR-NK and CAR-T. First Condor Life has developed three technology platforms with independent intellectual property rights: Trans-CAR, Boost-CAR, and R-Star. Clinical studies on solid tumor CAR-T targeting CLDN18.2, GCC, and Nectin-4 are currently underway in multiple hospitals.